drugset / Trial / NCT04773392

Simplified IMmunosuppressive Protocol Utilizing Low Dose EnvarsusXR

NCT04773392 ↗

RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to determine if the combination of once-daily tacrolimus extended-release (EnvarsusXR) and Azathioprine is non inferior with respect to the composite outcome of acute rejection, graft and patient survival as compared to a combination of twice-daily immediate release tacrolimus and mycophenolate mofetil/mycophenolic acid.

Timeline

Start
2021-11-23
Primary completion
2024-02-23
Completion
2024-02-23

Outcome

Outcome not reported

Stopped: “Research contract expired”

Drugs

EvaluationDrugModalityDoseRoute
Comparator Tacrolimus Small molecule 0.1 mg/kg —
Comparator Tacrolimus Small molecule 0.13 mg/kg —
Comparator Azathioprine Small molecule — —
Comparator Basiliximab Monoclonal antibody 20 mg —
Comparator Methylprednisolone Other / unclassified — —
Comparator Mycophenolate Mofetil Small molecule 1000 mg —
Comparator Prednisone Other / unclassified 5 mg Oral
Comparator Rabbit Anti Thymoglobulin (rATG) Unknown 6 mg/kg —
Comparator mycophenolic acid Small molecule 720 mg —

Indications